Galactokinase 1 Inhibition-Induced Cell Cycle Arrest and Apoptosis in Bladder Cancer Cells Is Associated with AKT Signaling Downregulation.

Surya P Singh, Ronghao Liu, Feng Yan, Qinggong Tang, Chinthalapally V Rao, Venkateshwar Madka

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Surya P SinghCenter for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.ORCID 0000-0002-1848-2779

Ronghao LiuStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA.

Feng YanStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA.

Qinggong TangStephenson School of Biomedical Engineering, University of Oklahoma, Norman, OK 73019, USA.ORCID 0000-0001-9499-5384

Chinthalapally V RaoCenter for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.ORCID 0000-0002-5715-7979

Venkateshwar MadkaCenter for Cancer Prevention and Drug Development, Stephenson Cancer Center, Hem-Onc Section, Department of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK 73104, USA.ORCID 0000-0002-8896-4095

Funding

Institutional Research Grant 134128-IRG-19-142-01

6 · The paper itself

Abstract

Bladder cancer (BCa) is the second most common cancer of the genitourinary tract globally. It has limited treatment options, high recurrence rate, and acquires resistance to platinum-based therapy. Therefore, identifying novel therapeutic targets is urgently needed. Analysis of the TCGA data revealed that the enzyme galactokinase-1 (GALK1) is overexpressed (

Indexed as

ApoptosisCell Cycle CheckpointsProto-Oncogene Proteins c-aktSignal TransductionUrinary Bladder NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationDown-RegulationGene Expression Regulation, NeoplasticHumansMembrane Potential, MitochondrialReactive Oxygen SpeciesProto-Oncogene Proteins c-aktReactive Oxygen Speciesapoptosisbladder cancercell cyclecpd36galactokinase-1

Identifiers

PMID41898771

DOI10.3390/ijms27062911

PMCPMC13026698

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.